Esperion Therapeutics, Inc.

How big is Esperion Therapeutics, Inc.?

As of Jun 18, Esperion Therapeutics, Inc. has a market capitalization of 218.21 million and reported net sales of 259.57 million with a net profit of -153.21 million over the latest four quarters. Shareholder's funds are -388.72 million, and total assets are 345.34 million.

As of Jun 18, Esperion Therapeutics, Inc. has a market capitalization of 218.21 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 259.57 million, while the sum of net profit for the same period is -153.21 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -388.72 million, and the total assets amount to 345.34 million.

What does Esperion Therapeutics, Inc. do?

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing oral therapies for managing elevated LDL cholesterol. As of March 2025, it reported net sales of $65 million and a net loss of $40 million, with a market cap of $218.21 million.

Overview: <BR>Esperion Therapeutics, Inc. is a lipid management company in the Pharmaceuticals & Biotechnology industry, focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). <BR><BR>Financial Snapshot: <BR>Net Sales: 65 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 218.21 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.12 <BR>Return on Equity: 23.06% <BR>Price to Book: -0.51 <BR><BR>Contact Details: <BR>Address: 3891 Ranchero Dr Ste 150, ANN ARBOR MI: 48108-2837 <BR>Tel: 1 734 8873903 <BR>Fax: 1 302 6555049 <BR>Website: http://www.esperion.com/

Should I buy, sell or hold Esperion Therapeutics, Inc.?

Who are in the management team of Esperion Therapeutics, Inc.?

As of March 2022, the management team of Esperion Therapeutics, Inc. includes Timothy Mayleben as President and CEO, with Nicole Vitullo as Lead Independent Director. The Board of Directors features independent members Jeffrey Berkowitz, Alan Fuhrman, Antonio Gotto, and Daniel Janney.

As of March 2022, the management team of Esperion Therapeutics, Inc. includes Mr. Timothy Mayleben, who serves as the President, Chief Executive Officer, and Director. Additionally, Ms. Nicole Vitullo is the Lead Independent Director. The Board of Directors also comprises Mr. Jeffrey Berkowitz, Mr. Alan Fuhrman, Dr. Antonio Gotto, and Mr. Daniel Janney, all serving as independent directors.

Is Esperion Therapeutics, Inc. overvalued or undervalued?

As of May 8, 2019, Esperion Therapeutics, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics and a concerning long-term performance, despite a recent short-term stock gain.

As of 8 May 2019, the valuation grade for Esperion Therapeutics, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company is considered overvalued given its negative P/E ratio, a price to book value of -0.57, and an EV to EBITDA ratio of -18.10. In comparison, Protalix Biotherapeutics, Inc. has a P/E of 20.08, highlighting a stark contrast in valuation metrics among peers.<BR><BR>Despite a notable 1-month stock return of 30.95%, which outperformed the S&P 500's 2.33% return, the long-term performance is concerning, with a 5-year return of -92.98% compared to the S&P 500's 96.61%. This suggests that while there may be short-term gains, the overall outlook for Esperion remains bleak, reinforcing the conclusion that the stock is overvalued.

Is Esperion Therapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, the trend is mildly bullish, supported by a bullish MACD and moving average, but mixed signals from the RSI and KST suggest a cautious outlook.

As of 3 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly chart and a bullish daily moving average. However, the weekly RSI indicates bearish momentum, while the monthly KST shows a bearish signal. The Bollinger Bands are mildly bullish on the weekly and bullish on the monthly, and Dow Theory reflects a mildly bullish stance across both time frames. Overall, the mixed signals suggest a cautious bullish outlook. Multi-period return data is not available for comparison with the S&P 500.